Press Releases

For FYB201, new data from the recently completed COLUMBUS-AMD phase III trial in patients with neovascular age-related macular degeneration (nAMD) are available.

The turnover of the Formycon group increased significantly compared with the first nine months of 2017.

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars

Formycon has significantly improved its revenue and earnings in the first quarter of 2018 compared to the same period of the previous year.

Formycon has ended the 2017 financial year successfully and has once again significantly advanced the development of its product candidates.

According to an interim result, the primary endpoint has been achieved in the COLUMBUS-AMD phase III trial, which is intended to demonstrate the efficacy, safety and immunogenicity of FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

In the COLUMBUS-AMD Trial the primary endpoint has been achieved, thus confirming comparable efficacy between FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

Formycon has ranked 7th in the FT1000 list compiled by the highly respected business newspaper the Financial Times and data provider Statista, making it the only biotech company to appear in the top ten.

Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon's biosimilar candidate for Stelara® (ustekinumab).

Formycon has again progressed well with the further development of its four biosimilars and confirmed the Euro 25 million sales target for whole of 2017.

The Supervisory Board of Formycon has extended the appointments of Dr. Carsten Brockmeyer, board member and CEO, and Dr. Nicolas Combé, board member and CFO, until June 30, 2022.

Formycon has accomplished a successful first half year in 2017. Phase III clinical trial of FYB201 is continuing to progress as planned, the implementation of development cooperation agreement for FYB202 is anticipated for second half of the year

Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.

The commercial performance of Formycon has again advanced as planned in the first quarter of 2017 and the development of its four biosimilar projects has progressed as expected.